Rifaximin Drug Asset Due Diligence Report 2026

This Rifaximin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

278

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Rifaximin can convert its Small molecule drug profile and Bacterial RNAP biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Rifaximin (query alias: rifaximin)
Modality / target	Small molecule drug; Bacterial RNAP; Bacterial RNAP inhibitors
Highest global status	Approved
Originator	Not disclosed
Active developers	Bausch Health Americas, Inc., ASKA Pharmaceutical Co., Ltd., Salix Pharma AB

The MCP disease footprint includes Hyperammonemia, Irritable bowel syndrome with diarrhea, Hepatic Encephalopathy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07522255	Phase 3	Not yet recruiting	78	Bloating responder rate
NCT07454408	Phase 1/2	Not yet recruiting	40	Incidence and severity of treatment-related adverse events (AEs) and serious adverse events (SAEs)
NCT07683936	Early Phase 1	Recruiting	26	Incidence and severity of treatment-related adverse events (AEs) and serious adverse events (SAEs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint.

Phase 2; n=5; evaluation: not stated. Reported fields: -; Improvement in Bloating Based on Overall Questionnaire Scoring = 4 participants ; -

Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial

Phase 3; n=152; evaluation: Negative. Reported fields: Survival(12-month) = 68.1 % ( 56.2 - 78.7); Survival(12-month) = 56.6 % ( 43.5 - 67.8)

Management of symptomatic uncomplicated diverticular disease (SUDD) of the colon with Clostridium butyricum CBM588 versus rifaximin: a retrospective cross-sectional study

Not Applicable; n=70; evaluation: Positive. Reported fields: Adequate symptom relief = 44.0 % ; Adequate symptom relief = 77.4 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Rifaximin addresses Hyperammonemia, Irritable bowel syndrome with diarrhea, Hepatic Encephalopathy. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2015-02-23	Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash	Approved	US$14,500.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Novel combination of rifaximin and clarithromycin for treating multidrug-resistant mycobacterium abscessus”. The milestone feed surfaced a patent-application signal described as “A pharmaceutical formulation of loperamide and rifaximin”. The milestone feed surfaced a patent-application signal described as “Purification method of rifaximin and application of rifaximin in rifaximin tablets”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO